Uncertainty exists as to the most appropriate dose of haloperidol in first-episode psychosis. This study set out to determine whether ultra-low doses of haloperidol could successfully treat patients with first-episode psychosis. Thirty-five patients with a first episode of psychosis were treated with haloperidol in an open label, fixed protocol over a 12-week period with doses restricted to 1 mg per day for the first 4 weeks. Twenty-nine (83%) remained on haloperidol after 12 weeks at a mean dose of 1.78 mg per day, 16 (55%) had stabilized on 1 mg/day or less. The mean percentage reduction in Positive and Negative Symptom Scale score between baseline and 6 and 12 weeks was 30.3% (SD 20.9%) and 41.4% (SD 16.6%), respectively. There were no significant differences in mean extrapyramidal symptom ratings between baseline and 12 weeks. Ultra-low doses of haloperidol are effective and well tolerated in first-episode psychosis. Initial doses should be maintained for a sufficient period of time to allow for the medication to take full effect.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington, DC
2.
Baldessarini R J, Cohen B M, Teicher M H (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry45: 79–91
3.
Barnes T R (1989) A rating scale for drug-induced akathisia. Br J Pharmacol154: 672–676
4.
Beasley C M, Dellva M A, Tamura R N, Morgenstern H, Glazer W M, Ferguson K, Tollefson G D (1999) Randomised double blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry174: 23–30
5.
Coryell W, Miller D D, Perry P J (1998) Haloperidol plasma levels and dose optimization. Am J Psychiatry155: 48–53
6.
Eklund K, Forsman A (1991) Minimal effective dose and relapse – double blind trial: haloperidol decanoate versus placebo. Clin Neuropharmacol14 (Suppl. 2): S7–S15
7.
Emsley R, the Risperidone Working Group (1999a) Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull25: 721–729
8.
Emsley R, Oosthuizen P P, Joubert A F, Hawkridge S M, Stein D J (1999b) Treatment of schizophrenia in low-income countries. Int J Neuropsychopharmacol2: 321–325
9.
Farde L, Nordstrom A L, Wiesel F, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine. relation to extrapyramidal side effects. Arch Gen Psychiatry49: 538–544
10.
First M B, Spitzer R L, Gibbon M, Williams J B W (1994) Structured clinical interview for DSM-IV axis I disorders, patient edn (SCID-P), version 2. New York State Psychiatric Institute, Biometrics Research, New York
11.
Guy W (1976) ECDEU assessment manual for psychopharmacology: publication ADM 76-338. US Department of Health, Education and Welfare, Rockville, MD
12.
Hoge S K, Appelbaum P S, Lawlor T, Beck J C, Litman R, Greer A, Gutheil T G, Kaplan E (1990) A prospective, multicenter study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry47: 949–956
13.
Johnson D A W, Ludlow J M, Street K, Taylor R D W (1987) Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised outpatients with schizophrenia. Br J Psychiatry151: 634–638
14.
Kane J M, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi J (1983) Low-dose neuroleptic treatment of outpatient schizophrenics. Arch Gen Psychiatry40: 893–896
15.
Kapur S, Remington G, Jones C, Roy P, Reed K, Houle S, Zipursky R B (1996a) What is the lowest effective dose of haloperidol? evidence from PET studies. Biol Psychiatry39: 513-513
16.
Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R (1996b) High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry153: 948–950
17.
Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry157: 514–520
18.
Kay S R, Fizbein A, Opler L A (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull13: 261–267
19.
Kelley M E, van Kammen D P, Allen D N (1999) Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am J Psychiatry156: 406–411
20.
Kulkarni J, Power P (1999) Initial treatment of first-episode psychosis. In McGorry P D, Jackson H J (eds), The recognition and management of early psychosis, pp. 184–205. Cambridge University Press, Cambridge
21.
Lee M A, Thompson P A, Meltzer H Y (1994) Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry55(Suppl. B): 82–87
22.
Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res35: 51–68
23.
Lieberman J A, Kane J M, Safferman A Z (1994) Predictors of response to clozapine. J Clin Psychiatry55 (Suppl. B): 126–128
24.
Lieberman J A, Koreen A R, Chakos M, Sheitman B, Woerner M, Alvir J, Bilder R (1996) Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry9: 5–9
25.
Lieberman J A and the HGDH Study Group (2000) Olanzapine vs. haloperidol in the treatment of first-episode psychosis. Paper presented at the Annual Meeting of the American Psychiatric Association, 13 May 2000
26.
Marder S R, Van Putten T, Mintz J, Lebell M, McKenzie J, May P R A (1987) Low and conventional-dose maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry44: 518–521
27.
Mayerhoff D, Loebel A, Alvir J M, Szymanski S, Geisler S, Borenstein M, Lieberman J A (1994) The deficit state in first-episode schizophrenia. Am J Psychiatry151: 1417–1422
28.
McEvoy J P, Hogarthy G E, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry48: 739–745
29.
McGorry P D (1992) The concept of recovery and secondary prevention in psychotic disorders. Austr NZ J Psychiatry26: 3–17
30.
Meltzer H Y, Okayli G (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry152: 183–190
31.
Power P, McGorry P D (1999) Initial assessment of first-episode psychosis. In McGorry P D, Jackson H J (eds), The recognition and management of early psychosis. A preventive approach, pp. 155–183. Cambridge University Press, Cambridge
32.
Remington G, Kapur S (1999) D2 and 5HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry60 (Suppl. 10): 15–19
33.
Simpson G M, Angus J W S (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand212: 11–19
34.
Szymanski S R, Cannon T D, Gallacher F, Erwin R J, Gur R E (1996) Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry153: 519–525
35.
Thomas C S, Lewis S (1998) Which atypical antipsychotic?Br J Psychiatry172: 106–109
36.
Tollefson G D, Sanger T M (1997) Negative symptoms: a path analytical approach to a double-blind, placebo-and haloperidol controlled clinical trial with olanzapine. Am J Psychiatry154: 466–474
37.
Tollefson G D, Sanger T M, Lu Y, Thieme M E (1998) Depressive signs and symptoms in schizophrenia. Arch Gen Psychiatry55: 250–258
38.
Van Putten T, Marder S R, Mintz J (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry47: 754–758
39.
Wolkin A, Barouche F, Wolf A P (1989) Dopamine receptor blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry146: 905–908
40.
Zhang-Wong J, Zipursky R B, Beiser M, Bean G (1999) Optimal haloperidol dosage in first-episode psychosis. Can J Psychiatry44: 164–167
41.
Zimbroff D L, Kane J M, Tamminga C A, Daniel D G, Mack R J, Wozniak P J, Sebree T B, Wallin B A, Kashkin K B, and the Sertindole Study Group (1997) Controlled, dose–response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry154: 782–791
